Descarga: The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients
Archivo: covid-19/The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. BLOOD.pdf
The BTK-inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft versus host disease. The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury and death was previously demonstrated in a highly relevant, lethal flu animal model.1 We therefore sought to clarify the impact of ibrutinib in COVID-19 patients. We care for 600-800 Waldenstrom’s Macroglobulinemia (WM) patients per year; approximately 300 of whom are on a BTK-inhibitor. We identified 6 patients receiving ibrutinib for Waldenstrom’s Macroglobulinemia who were diagnosed with COVID-19; these patients consented to the use of their data. Their clinical characteristics appear in Table 1. Their median age was 66 years, and five were on the recommended treatment dose of 420 mg/day; the sixth patient was on a reduced dose of 140 mg/day because of arthralgias. For all patients, the median time on ibrutinib was 52 months. Their median time with COVID-19 related symptoms prior to diagnostic testing was 5 days, and since diagnosis of COVID-19 was 22 days. All 6 patients experienced cough and fever as prodromal symptoms. The 5 patients on ibrutinib at 420 mg/day experienced no dyspnea and required no hospitalization. Their course was marked by steady improvement, and resolution or near resolution of COVID-19 related symptoms in all five of these patients during the follow-up period.
Documento PDF detectado.